Study S000731

Semaglutide, 2.4mg, Once Weekly: Effects on Beta-cell Preservation and Reduction of Intrahepatic Triglyceride Content in Obese Youth With Prediabetes (IGT)/Early Type 2 Diabetes (T2D) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

ClinicalTrials.gov record

Registration

Registration: NCT05067621
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 60
Start: 2023-07-17
Primary completion: 2026-12
Lead sponsor: Yale University
Conditions: Type 2 Diabetes Mellitus; Impaired Glucose Tolerance; Non-Alcoholic Fatty Liver Disease; Obesity, Childhood
Interventions: DRUG:Semaglutide Pen Injector; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: NIH:2R01DK111038-06A1

Registered primary outcomes

Change in Oral Disposition Index (oDI) [Baseline and 6 months]
Change in Protein Density Fat Fraction (PDFF) [Baseline and 6 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0040528	From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis Manik Aggarwal, Clinical Liver Disease	2023	Other	PMID 36938314 DOI	cites ClinicalTrials.gov:NCT05067621